Creso Pharma Ltd (ASX: CPH) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Creso Pharma Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $111.60 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 1.23 billion
Earnings per share -0.019
Dividend per share N/A
Year To Date Return 4.88%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Creso Pharma Ltd (ASX: CPH)
Latest News

CPH ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Creso Pharma Ltd

Creso Pharma Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its product portfolio includes Creso Animal Health products, Nutraceutical products, Topical products, Therapeutics products, and Lifestyle products. The company has operations in Switzerland, Canada, Colombia, Israel and Australia. The company derives prime revenue from the Europe andMiddle East regions.

CPH Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
18 Jan 2022 $0.09 $0.01 11.63% 3,115,955 $0.09 $0.10 $0.09
17 Jan 2022 $0.09 $0.00 0.00% 2,814,550 $0.09 $0.09 $0.09
14 Jan 2022 $0.09 $0.00 0.00% 1,648,273 $0.09 $0.09 $0.09
13 Jan 2022 $0.09 $0.01 11.90% 4,665,228 $0.09 $0.09 $0.09
12 Jan 2022 $0.08 $0.00 0.00% 427,213 $0.08 $0.09 $0.08
11 Jan 2022 $0.08 $0.00 0.00% 1,011,326 $0.08 $0.09 $0.08
10 Jan 2022 $0.08 $0.00 0.00% 811,586 $0.08 $0.09 $0.08
07 Jan 2022 $0.08 $0.00 0.00% 547,392 $0.09 $0.09 $0.08
06 Jan 2022 $0.09 $0.00 0.00% 3,574,654 $0.09 $0.09 $0.08
05 Jan 2022 $0.09 $0.01 12.35% 3,276,194 $0.08 $0.09 $0.08
04 Jan 2022 $0.08 $0.00 0.00% 1,795,647 $0.08 $0.08 $0.08
31 Dec 2021 $0.08 $0.00 0.00% 2,369,663 $0.08 $0.08 $0.08
30 Dec 2021 $0.08 $0.00 0.00% 2,912,123 $0.08 $0.08 $0.08
29 Dec 2021 $0.08 $0.00 0.00% 2,749,342 $0.08 $0.08 $0.08
24 Dec 2021 $0.08 $0.00 0.00% 442,887 $0.08 $0.08 $0.08
23 Dec 2021 $0.08 $0.00 0.00% 738,898 $0.08 $0.08 $0.08
22 Dec 2021 $0.08 $0.00 0.00% 2,531,616 $0.08 $0.08 $0.08
21 Dec 2021 $0.08 $0.00 0.00% 4,400,796 $0.08 $0.08 $0.08

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
02 Nov 2021 Adam Blumenthal Issued 37 $4,925,502
Issue of options. As per announcement on 08/11/2021
02 Nov 2021 James Ellingford Issued 384 $49,941
Issue of options. As per announcement on 08/11/2021
02 Nov 2021 Boaz Wachtel Issued 2 $381,333
Issue of options. As per announcement on 08/11/2021.
14 Jul 2021 Boaz Wachtel Issued 500 $65,000
Issue of securities.
14 Jul 2021 Adam Blumenthal Issued 12 $1,560,000
Issue of securities.
14 Jul 2021 James Ellingford Issued 500 $65,000
Issue of securities.
07 Jul 2021 Adam Blumenthal Sell 32 $4,493,912
On-market trade.
07 Jul 2021 Adam Blumenthal Sell 87 $7,903,077
Off-market trade.
09 Mar 2021 James Ellingford Transfer 797 $159,500
Off-market transfer.
22 Jan 2021 Adam Blumenthal Issued 87 $18,879,575
Issue of securities. As per announcement on 27/01/2021.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Adam Blumenthal Non-Executive DirectorNon-Executive Chairman Nov 2015
Mr Blumenthal has over 10 years experience in Investment Banking and Corporate Finance. He has exposure to Australian and International markets, having provided capital raising and financing solutions to an number of unlisted and listed companies. Adam has played a lead role in advising and supporting multiple organisations across a broad spectrum of industries, using his experience and network of international contacts to provide corporate advisory and capital markets input. He has successfully brought to market several Medical Marijuana companies spanning Israel, Canada, Switzerland and Australia. He has also been actively involved in the Mining, Cyber Security, Health Care and IT sectors. Adam is a director of EverBlu Capital Pty Ltd, the Company's appointed corporate advisor and lead manager to the various capital raisings undertaken by the Company in CY2020. Outside of his formal business activities, Adam has lectured at a leading Sydney University covering corporate governance, corporate social responsibility and ASX listings - both at an undergraduate and postgraduate level. He is a member of the Israel Business Club Sydney (IBCS).
Dr James Anthony Ellingford Executive Director Nov 2015
Dr Ellingford has vast experience in the international arena and has successfully developed close ties with both financial institutions as well as governments throughout the world. Dr Ellingford's professional life culminated in being President of an international publicly listed billion-dollar business with its headquarters in Geneva, Switzerland and New York, USA. Dr Ellingford used to lecture MBA students in Corporate Governance at a leading Sydney University and has a keen interest in ethics. Dr Ellingford is chairman of Risk Committee.
Mr Boaz Wachtel Non-Executive Director Nov 2015
Mr Wachtel was Co-Founder and former Managing Director of MMJ-PhytoTech Ltd, Australia's first publicly traded Medical Cannabis Company. Co-founder of IMCPC - International Medical Cannabis Patient Coalition. He is an Israeli medical cannabis pioneer/activist, who formulated and assisted the Ministry of Health with the implementation of the National Medical Cannabis Program - one of only few national programs in the world. He is a frequent lecturer and adviser to governments, national committees, business and NGO's on medical cannabis program formulation, grow operations, international laws and UN drug convention compliance, as well as the founder (1999) and former Chairman of the Green Leaf Party, an Israeli political party for cannabis legalisation/medicalisation, human rights and ecology. Mr Wachtel is member of Risk Committee.
Mr Bruce Andrew Linton Non-Executive Director Jan 2022
Mr Linton is a cannabis executive and has sector experience as a founder, CEO, Board member and advisor to a number of global cannabis and psychedelic focused companies. Mr Linton's experience include his role as founder, Chairman and ex-CEO of Canopy Group Corporation. Mr Linton was also responsible for securing market support for 16 funding rounds and progressing over 30 M&A opportunities. He led Canopy Growth through its start-up phase to becoming the first producing cannabis company to list on the New York Stock Exchange. Following his departure from Canopy Growth, he has led direct investments into the cannabis and psychedelic sector while undertaking management and strategic advisory roles. These include being Executive Chairman of Gage Cannabis Co. and a Director of psychedelic medicines company, Mind Medicines Inc.
Mr William Lay Chief Executive OfficerManaging Director Jan 2022
Mr Lay is an experienced cannabis executive and previously served as Executive Vice President - Strategy, Origination & Operations at Creso Pharma (refer ASX announcement: 6 September 2021). Mr Lay began his career with Canadian full service financial investment bank, BMO Capital Markets through roles across Canada and London. Shortly after his time with BMO Capital Markets, Mr Lay joined Canopy Growth Corporation (TSE: WEED, NASDAQ: CGC) as an M&A Associate, before being promoted to Associate Director, M&A, in 2019. In this role, he assessed and effected multiple transactions locally and internationally, while concurrently progressing corporate strategy initiatives across the group. Over the last four years, Mr Lay has managed and supported cannabis M&A transactions, including managing the acquisition in the history of the cannabis sector.
Mrs Micheline MacKay Executive Director Jan 2022
Mrs MacKay has 22 years of experience in regulatory environments, including pharmaceuticals, medical devices, and government regulated industries. She has held leadership positions for many years in different areas with a focus on business improvements and product development from laboratory scale to commercial operations. Mrs MacKay is currently the Corporate Manager of Creso Pharma's wholly owned Canadian subsidiary, Mernova Medicinal Inc. (Mernova). She has been in the position for nearly three years and is responsible for multiple functions including HR, quality assurance, and regulatory affairs. Mrs MacKay is the Health Canada designated Responsible Person in Charge at Mernova. She has practical experience in managing a business through specified key performance indicators, managing budgets, conducting regular audits and performance management.
Mr Winton William Willesee Joint Company Secretary Oct 2018
Ms Erlyn Dale Joint Company Secretary Oct 2018
Christopher Grundy Chief Financial Officer
Erlyn Dale Joint Company Secretary
Winton William Willesee Joint Company Secretary

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Atlantic Capital Holdings Pty <Atlantic Capital A/C> 139,415,432 14.62%
Hsbc Custody Nominees (Australia) Limited 33,358,651 3.50%
Suburban Holdings Pty Ltd<The Suburban Super Fund A/C> 27,507,750 2.88%
Jamber Investments Pty Ltd <The Amber Schwarz Fam A/C> 20,200,000 2.12%
Citicorp Nominees Pty Limited 19,026,497 2.00%
Mr William James Fleming 16,600,000 1.74%
Miriam Halperin Wernli 13,333,333 1.40%
J P Morgan Nominees Australia Pty Limited 8,764,097 0.92%
International Water & Energy Savers Ltd 8,300,000 0.87%
RS Family Holdings Pty Ltd <The Ruth Simon Family A/C> 8,158,803 0.86%
Anglo Australasia Holdings Pty Ltd <Anglo Australasia A/C> 7,083,333 0.74%
Mr Lisheng Wang 5,050,000 0.53%
Mr Kenneth Joseph Hall <Hall Park A/C> 5,000,000 0.52%
Chincherinchee Nominees Pty Ltd 4,436,427 0.47%
S3 Consortium Holdings Pty Ltd <Nextinvestors Dot Com A/C> 4,300,000 0.45%
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 4,205,098 0.44%
Tenorio Pty Limited <Tenorio A/C> 3,581,427 0.38%
Mr Matthew Clarke Mallet 3,400,000 0.36%
Ubs Nominees Pty Ltd 3,192,251 0.33%
Comsec Nominees Pty Limited 3,176,508 0.33%